Color Masking Potential of Bioactive and ICON Materials
Launched by KING ABDULLAH UNIVERSITY HOSPITAL · May 3, 2024
Trial Information
Current as of November 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying different materials used to treat white spot lesions (WSLs) on teeth that can appear after wearing braces. WSLs are areas where the enamel has lost minerals, but they haven’t developed into cavities yet. The trial is comparing two treatments: ICON resin infiltration, which is considered the gold standard for this kind of issue, and a bioactive glass adhesive known as HI-Bond. Researchers want to find out if both treatments can effectively mask the color of these white spots and whether they help to add minerals back into the affected teeth.
To participate in this study, patients should be between the ages of 4 and 17 and have specific types of WSLs on their front or side teeth, without any previous dental work on those teeth. However, certain individuals are excluded, such as those with cavities, developmental defects in their teeth, or specific health conditions like diabetes. Participants can expect to receive either of the two treatments and contribute to important research that could help improve dental care for others with similar issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria: Patients with teeth and WSL fullfiling the following criteria will be included in the study:
- • 1. Anterior and premolar maxillary and mandibular teeth.
- • 2. Teeth with no previous restorations.
- • 3. post-orthodontic white spot lesions WSL with no adjacent restorations in the same tooth.
- • 4. WSL on Labial surfaces of maxillary or mandibular anterior and premolars teeth.
- • Exclusion Criteria: The following will be excluded from the study,
- • 1. Cavitated enamel surface that requires direct composite restorations.
- • 2. Presence of developmental enamel defects on the proposed teeth.
- • 3. Diabetic patients and patients with metabolic syndrome.
- • 4. Pregnant ladies.
- • 5. Smoker patients.
About King Abdullah University Hospital
King Abdullah University Hospital (KAUH) is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Located in Jordan, KAUH is committed to enhancing medical knowledge and improving treatment outcomes by conducting rigorous clinical trials across various therapeutic areas. The hospital is equipped with state-of-the-art facilities and a multidisciplinary team of healthcare professionals, ensuring the highest standards of research integrity and participant safety. Through its collaborative approach and focus on evidence-based medicine, KAUH aims to contribute significantly to the global medical community and the well-being of patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Irbid, None Selected, Jordan
Patients applied
Trial Officials
Zakereyya SM Albashaireh, PhD
Principal Investigator
Jordan University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported